Skip to content
AnalystLens

IDEXX Laboratories Annual Report, Year Ended Dec 31, 2012

Filing Date
Filed February 19, 2013
Period End
December 31, 2012
Security
IDXX
One revenue dollarkept$0.14
In the record · 2016–202610-K1110-Q338-K98

IDXX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 98 current reports (8-K) between 2016 and 2026.

  1. FY2016 annual report10-K · Feb ’17Feb ’17
  2. Leadership change8-K · Oct ’19Oct ’19
  3. Material agreement8-K · Dec ’21Dec ’21
  4. Leadership change8-K · Jan ’26Jan ’26

Summary

Summary of the 10-K filed February 19, 2013. Cited figures are marked; the original filing is the authoritative source.

IDEXX Laboratories' FY2012 10-K shows a company that grew revenue 6.1% to $1.293 billiona (organic growth 6.7%) and expanded operating margin to 20.3% from 19.4%, with diluted EPS rising 14% to $3.17.

Growth was led by the Companion Animal Group (CAG), which rose 7.3% to $1.07 billionb, driven by reference laboratory services (+8.9%), VetLab consumables (+9.0%) and practice management (+11.3%). LPD was the weak spot, with revenue down 7.9% on EU BSE testing reductions, and management now estimates BSE product revenue at under $10 million. Cash generation and balance sheet are solid.

Operating cash flow was $230.3 million, cash rose to $224.0 millionc, and total debt fell to $214.5 million from $246.4 million. The company spent $132.3 million repurchasing 1.5 million shares, leaving 2.9 million shares under its 48 million-share authorization. IDEXX has never paid a cash dividend and has no present intention to do so.

Capital spending is planned at about $75 milliond for 2013, including a headquarters expansion. Key risks include the February 2013 FTC consent order, which limits exclusive distribution to two of the three largest U.S. distributors and changes the MWI relationship from January 2013. Other risks are concentration in Butler Schein (9% of revenue), customer consolidation through corporate hospital owners and buying groups, sole-source supply dependence on Ortho for chemistry slides, and about 41% of revenue from outside the U.S. The new Westbrook administrative building is expected to be substantially complete in late 2013, and the 2013 R&D tax credit reinstatement should lower the effective tax rate by roughly 2 points.

Key Highlights

  1. Revenue grew 6.1% to $1,293.3 million in 2012 (6.7% organic); diluted EPS rose 14% to $3.17 from $2.78.
  2. Operating income rose 11.1% to $262.6 million, and operating margin expanded to 20.3% from 19.4%.
  3. CAG drove growth with 7.3% revenue growth to $1.07 billion, led by reference laboratory services (+8.9%) and VetLab consumables (+9.0%).
  4. LPD revenue fell 7.9% to $86.7 million due to EU BSE testing reductions; BSE product revenue is now under $10 million.
  5. Operating cash flow of $230.3 million funded $65.5 million in capex and $132.3 million in share repurchases, and cash ended at $224.0 million.
  6. Total debt declined to $214.5 million from $246.4 million; the $300 million revolver had $87 million of remaining availability at year-end.
  7. The FTC consent order (final approval February 11, 2013) limits exclusive distribution arrangements to two of three major U.S. distributors and will change the MWI agreement from January 2013.

Follow one dollar

Of each $1.00 of revenue in FY2012, IDEXX Laboratories kept $0.14.

  1. Revenue$1.29B100.0%
  2. Cost of revenue−$594.2M45.9%
  3. Gross profit$699.1M54.1%
  4. Operating costs−$436.6M33.8%
  5. Operating income$262.6M20.3%
  6. Interest, other & tax−$84.3M6.5%
  7. Net income$178.3M13.8%
Computed from 10-KFY2012filed February 19, 2013Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2012 revenue went

$1.29B
  • Cost of revenue: $594.2M, 46% of revenue
  • Other operating costs: $354.6M, 27% of revenue
  • Net income: $178.3M, 14% of revenue
  • R&D: $82.0M, 6.3% of revenue
  • Interest, other & tax: $84.3M, 6.5% of revenue

Kept 14% as net income

Full revenue history →

Financial Statements

FY2012 against FY2011

Line itemFY2012FY2011Change
Revenue$1.29B$1.22B+6.1%
Cost of Revenue$594.19M$572.18M+3.8%
Gross Profit$699.15M$646.51M+8.1%
R&D Expenses$82.01M$76.04M+7.9%
Operating Income$262.56M$236.22M+11.1%
Interest Expense$3.85M$3.55M+8.5%
Net Income$178.27M$161.79M+10.2%
EPS (Basic)$1.62$1.43+13.7%
EPS (Diluted)$1.58$1.39+14.0%
Shares Outstanding (Basic)109.97M113.58M−3.2%
Shares Outstanding (Diluted)112.31M116.43M−3.5%

Frequently Asked Questions

  1. Does IDEXX pay a dividend?

    No. IDEXX has never paid cash dividends on its common stock and has no present intention to do so. Capital is returned through share repurchases instead, with $132.3 million repurchased in 2012 and 2.9 million shares remaining under the authorization.

  2. What is the impact of the FTC Consent Agreement?

    The ten-year consent order, finalized February 11, 2013, allows IDEXX exclusive distribution agreements with only two of three major U.S. distributors (MWI, Butler Schein, Webster). The MWI agreement was modified effective January 1, 2013 to permit MWI to carry competitors' products without restriction, which management expects to increase competitor sales through MWI. Management says it does not expect a material impact but acknowledges the risk that sales resources may be less effective.

  3. How concentrated is IDEXX's customer base?

    Concentration is meaningful. Butler Schein Animal Health Supply accounted for 9% of consolidated revenue in 2012, 2011 and 2010, and it was 7% of net receivables at year-end 2012. Distributor consolidation and the growth of corporate hospital owners such as VCA Antech, Banfield and National Veterinary Associates, plus buying consortiums, add pricing pressure and purchasing risk.

  4. What are the main sources of growth and risk in the outlook?

    Growth is expected from the reference laboratory network, consumables tied to the Catalyst Dx and ProCyte Dx installed base, practice management tools such as Pet Health Network Pro, and dairy and OPTI Medical. Headwinds include reduced BSE testing in Europe, lower Aflatoxin M1 testing in China in 2013, and currency: a 10% stronger U.S. dollar would reduce 2013 operating income by about $8 million. Planned 2013 capex is about $75 million, and the R&D tax credit reinstatement should reduce the effective tax rate by about 2 percentage points.